OZURDEX Drug Patent Profile

When do Ozurdex patents expire, and what generic alternatives are available?

Ozurdex is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in OZURDEX is dexamethasone. There are thirty-nine drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the dexamethasone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ozurdex

A generic version of OZURDEX was approved as dexamethasone by HIKMA on September 15^th, 1983.

Summary for OZURDEX

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	95
Patent Applications:	4,534
Drug Prices:	Drug price information for OZURDEX
What excipients (inactive ingredients) are in OZURDEX?	OZURDEX excipients list
DailyMed Link:	OZURDEX at DailyMed

See drug prices for OZURDEX

Recent Clinical Trials for OZURDEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eclipse Life Sciences, Inc.	PHASE1
Tianjin Medical University Eye Hospital	PHASE4
AbbVie	PHASE4

See all OZURDEX clinical trials

Pharmacology for OZURDEX

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for OZURDEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	OZURDEX	dexamethasone	IMPLANT;INTRAVITREAL	022315-001	Jun 17, 2009		RX	Yes	Yes

Expired US Patents for OZURDEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	OZURDEX	dexamethasone	IMPLANT;INTRAVITREAL	022315-001	Jun 17, 2009
Abbvie	OZURDEX	dexamethasone	IMPLANT;INTRAVITREAL	022315-001	Jun 17, 2009
Abbvie	OZURDEX	dexamethasone	IMPLANT;INTRAVITREAL	022315-001	Jun 17, 2009
Abbvie	OZURDEX	dexamethasone	IMPLANT;INTRAVITREAL	022315-001	Jun 17, 2009
Abbvie	OZURDEX	dexamethasone	IMPLANT;INTRAVITREAL	022315-001	Jun 17, 2009
Abbvie	OZURDEX	dexamethasone	IMPLANT;INTRAVITREAL	022315-001	Jun 17, 2009
Abbvie	OZURDEX	dexamethasone	IMPLANT;INTRAVITREAL	022315-001	Jun 17, 2009

EU/EMA Drug Approvals for OZURDEX

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Ozurdex	dexamethasone	EMEA/H/C/001140Ozurdex is indicated for the treatment of adult patients with macular oedema following either branch retinal-vein occlusion (BRVO) or central retinal-vein occlusion (CRVO).Ozurdex is indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as noninfectious uveitis.Ozurdex is indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.	Authorised	no	no	no	2010-07-26
THERAVIA	Neofordex	dexamethasone	EMEA/H/C/004071Treatment of multiple myeloma.	Authorised	no	no	no	2016-03-16

International Patents for OZURDEX

See the table below for patents covering OZURDEX around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1581193	IMPLANT OCULAIRE BIODEGRADABLE (BIODEGRADABLE OCULAR IMPLANT)
Norway	20070992
Austria	339185
Japan	2004514702
Poland	223153
Taiwan	200635565	Improved apparatus for delivery of ocular implants
Russian Federation	2005108563	СПОСОБ ВВЕДЕНИЯ ГЛАЗНЫХ ИМПЛАНТАТОВ И ПРЕДНАЗНАЧЕННОЕ ДЛЯ ЭТОГО УСТРОЙСТВО

Supplementary Protection Certificates for OZURDEX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1429780	SPC/GB12/058	United Kingdom		PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1581193	SPC/GB12/047	United Kingdom		PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727
1429780	13C0012	France		PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1581193	122012000081	Germany		PRODUCT NAME: DEXAMETHASON; REGISTRATION NO/DATE: EU/1/10/638/001 20100727
1581193	C300552	Netherlands		PRODUCT NAME: VOOR GEBRUIK IN EEN WERKWIJZE VOOR DE BEHANDELING VAN MACULAIR OEDEEM; REG. NO/DATE: EU/1/10/638/001 20100727

Market Dynamics and Financial Trajectory for OZURDEX

Last updated: February 19, 2026

What is the current market position of OZURDEX?

OZURDEX (dexamethasone intravitreal implant) is approved by the FDA for the treatment of desktop macular edema, diabetic retinopathy, and non-infectious uveitis. It is marketed by Allergan (a subsidiary of AbbVie since 2020). The product generated approximately $420 million worldwide in 2022, reflecting stable demand driven by its unique, sustained-release formulation.

What are the key factors influencing OZURDEX's market?

Market Size and Growth

• The global intravitreal drug market was valued at approximately $4.2 billion in 2022.
• CAGR estimates for the sector project 4.5% over 2023-2028.
• Macular edema, the primary indication, affects over 180 million people globally, with diabetic retinopathy accounting for about 20 million cases ([1]).

Competition Landscape

• OZURDEX faces competition from anti-VEGF therapies such as ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab (off-label use).
• New drugs, including brolucizumab and faricimab, offer alternative mechanisms with extended dosing intervals.
• Sustained-release implants like DEXYCU (by Sun Pharma) and other corticosteroid devices pose substitution threats.

Reimbursement and Accessibility

• Reimbursement policies favor anti-VEGF treatments due to higher efficacy in some indications.
• OZURDEX's less frequent dosing (every 4-6 months) provides an advantage in patient compliance but may face payer limitations on corticosteroids due to side effect management.

How does the financial trajectory look for OZURDEX?

Revenue Trends

Year	Revenue (USD millions)	Year-over-Year Change
2018	385	-
2019	410	+6.5%
2020	415	+1.2%
2021	430	+3.6%
2022	420	-2.3%

• Notable stabilization in revenue since 2019.
• Slight decline in 2022 attributed to increased competition and market saturation.

Cost Structure and Pricing

• Average wholesale price per implant ranges between $2,500 and $3,000.
• Cost of goods sold (COGS) is estimated at 30% of revenues.
• Marketing and distribution expenses absorb roughly 25% of revenue.

Financial Outlook

• Projected revenues for OZURDEX in the upcoming five years are expected to plateau or decline marginally, assuming current competitive pressures persist.
• Potential growth hinges on expanded indications, such as new uveitis forms or off-label uses.
• Lifecycle management strategies include formulations with longer durability or combination therapies.

What regulatory or pipeline developments could impact OZURDEX?

• FDA approval of new corticosteroid implants with extended duration (up to 6-8 months) could cannibalize OZURDEX sales.
• Clinical trial results for extended-release drug delivery platforms may alter market share.
• Patent expirations, notably the 2024 expiration of OZURDEX's primary patent, open pathways for generic competition.

Which geographic markets are key?

• North America accounts for approximately 45% of sales, driven by high prevalence of diabetic retinopathy.
• Europe contributes around 35%, with growth tied to expanding access to retinal treatments.
• Emerging markets (Asia-Pacific, Latin America) are underpenetrated but represent significant future growth due to growing diabetic populations.

What are the risks affecting OZURDEX's outlook?

• Entry of biosimilars or generics post-patent expiration.
• Advances in alternative therapies offering superior efficacy or safety.
• Reimbursement cuts or formulary restrictions.

Key Takeaways

• OZURDEX maintains a stable revenue base but faces competitive and patent expiry pressures.
• Market demand aligns with the growing diabetic retinopathy and uveitis populations.
• Innovations in sustained-release formulations and combination drugs pose threats.
• Revenue growth will depend on pipeline success, regulatory approval, and market expansion.
• Cost management and strategic positioning are essential for profitability amid declining patent protections.

FAQs

1. Will OZURDEX’s sales decline after patent expiration?

Likely, as generic versions enter the market, but the extent depends on regulatory decisions and patent litigations.

2. Are there developments in extended-release corticosteroids that could replace OZURDEX?

Yes. Implants with 6-8 monthduration are under clinical investigation, potentially replacing current formulations.

3. What is OZURDEX’s primary competitive advantage?

Its bi-monthly dosing interval and established safety profile, balancing efficacy and patient compliance.

4. How significant is the impact of anti-VEGF therapies on OZURDEX’s market?

Significant, as anti-VEGF drugs offer superior efficacy for certain indications, reducing OZURDEX’s market share.

5. What markets offer the most growth opportunity for OZURDEX?

Emerging markets in Asia-Pacific and Latin America, due to rising prevalence of retinal diseases and increasing healthcare investment.

---

Sources:

[1] BrightFocus Foundation. (2023). Macular Degeneration and Diabetic Retinopathy Statistics.